- Home
- HIND vs IMNN Comparison
HIND vs IMNN Comparison
Compare HIND & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIND
- IMNN
- Stock Information
- Founded
- HIND N/A
- IMNN 1982
- Country
- HIND United States
- IMNN United States
- Employees
- HIND N/A
- IMNN N/A
- Industry
- HIND
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- HIND
- IMNN Health Care
- Exchange
- HIND Nasdaq
- IMNN Nasdaq
- Market Cap
- HIND 10.3M
- IMNN 12.1M
- IPO Year
- HIND 2016
- IMNN 1985
- Fundamental
- Price
- HIND N/A
- IMNN $6.62
- Analyst Decision
- HIND
- IMNN Buy
- Analyst Count
- HIND 0
- IMNN 2
- Target Price
- HIND N/A
- IMNN $210.00
- AVG Volume (30 Days)
- HIND N/A
- IMNN 288.2K
- Earning Date
- HIND N/A
- IMNN 08-05-2025
- Dividend Yield
- HIND N/A
- IMNN N/A
- EPS Growth
- HIND N/A
- IMNN N/A
- EPS
- HIND N/A
- IMNN N/A
- Revenue
- HIND N/A
- IMNN N/A
- Revenue This Year
- HIND N/A
- IMNN N/A
- Revenue Next Year
- HIND N/A
- IMNN N/A
- P/E Ratio
- HIND N/A
- IMNN N/A
- Revenue Growth
- HIND N/A
- IMNN N/A
- 52 Week Low
- HIND N/A
- IMNN $4.83
- 52 Week High
- HIND N/A
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- HIND N/A
- IMNN 41.12
- Support Level
- HIND N/A
- IMNN $6.40
- Resistance Level
- HIND N/A
- IMNN $7.21
- Average True Range (ATR)
- HIND 0.00
- IMNN 0.68
- MACD
- HIND 0.00
- IMNN 0.16
- Stochastic Oscillator
- HIND 0.00
- IMNN 16.78
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).